The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...

SINGAPORE - An injectable drug used to treat obesity is now available via prescription from any licensed physician in ...

Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes.

The demand for obesity drugs in India surges as Eli Lilly and Novo Nordisk vie for market share. Meanwhile, President Trump ...

Novo Nordisk submits a higher 7.2 mg dose of Wegovy for EMA approval, backed by trials showing 21% weight loss in obesity and ...

Novo Nordisk has submitted a new, higher dose of its obesity treatment, Wegovy, for approval to the European Medicines Agency ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Investing.com -- Novo Nordisk (NYSE: NVO) stock rose 1% after the company announced it has submitted an application to the ...